TheraRadar
← Back
Data updated: Jun 28, 2026

JUBILANT CADISTA

Generics

JUBILANT CADISTA is a generic drug manufacturer focused on Neurology, Infectious Disease, Dermatology.

1988
Since
25
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

JUBILANT CADISTA's Key Drugs

JUBILANT CADISTA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

JUBILANT CADISTA's Recent FDA Approvals

New NDA/BLA approvals for JUBILANT CADISTA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

JUBILANT CADISTA's Therapeutic Areas

JUBILANT CADISTA's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Infectious Disease, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 33%
4 drugs
Infectious Disease 17%
2 drugs
Dermatology 17%
2 drugs
Gastroenterology 17%
2 drugs
Cardiovascular 17%
2 drugs

JUBILANT CADISTA Pipeline Snapshot

Active clinical trials for JUBILANT CADISTA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling